Literature DB >> 7130397

Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier).

E J Schaefer, L L Kay, L A Zech, H B Brewer.   

Abstract

Tangier disease is a rare familial disorder characterized by enlarged orange tonsils, transient peripheral neuropathy, hepatosplenomegaly, and lymphadenopathy, as well as striking reductions in plasma high density lipoproteins (HDL) and their major protein constituents, apolipoproteins (apo)A-I and A-II. In order to test the hypothesis that Tangier patients have abnormal apoA-I or apoA-II, the in vitro lipoprotein binding and in vivo metabolic characteristics of these proteins isolated from normal and Tangier plasma, were studied in normal subjects and patients with Tangier disease. After incubation with normal plasma, significantly greater percentages of radiolabeled Tangier apoA-I were associated with the 1.063-g/ml supernate (6%) and the 1.21 g/ml infranate (19%), and a lower percentage with HDL (75%), than those observed for normal apoA-I (2, 8, and 90%, respectively). In contrast, the lipoprotein binding properties of normal and Tangier apoA-II were very similar. Following the injection of radiolabeled normal and Tangier apoA-I into normal subjects (n = 4), the mean residence times of the specific activity for apoA-I(Tangier) were significantly lower, both in plasma (1.29 d) and in HDL (1.34 d), than those observed for normal apoA-I (3.80 and 4.06 d). In Tangier homozygotes the decay rates of these tracers were very rapid and were similar. No significant differences between the kinetics of normal and Tangier apoA-II were observed in normal subjects (n = 2). Tangier homozygotes (n = 3) had mean plasma HDL cholesterol, apoA-I, and apoA-II concentrations that were 4, 2, and 11% of normal (n = 24), respectively, whereas for heterozygotes (n = 3) these values were 46, 62, and 68% of normal. In homozygotes, in contrast to normals or heterozygotes, a significant fraction of both apoA-I and apoA-II were found in the 1.063-g/ml supernate instead of in HDL. Homozygotes had apoA-I(Tangier) synthesis rates and residence times that were 41 and 5% of values observed for normal apoA-I in normal subjects, and for apoA-II in homozygotes, these parameters were 63 and 18% of normal. Heterozygotes had apoA-I synthesis rates and residence times that were 92 and 66% of normal, and for apoA-II these values were 101 and 64% of normal. These data are consistent with the concept that apoA-I(Tangier) is functionally and metabolically distinct from normal apoA-I, and is the cause of the striking hypercatabolism of apoA-I and apoA-II, and the lipoprotein abnormalities observed in Tangier disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7130397      PMCID: PMC370306          DOI: 10.1172/jci110705

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Apoprotein A metabolism in Tangier disease.

Authors:  G Assmann; A Capurso; E Smootz; U Wellner
Journal:  Atherosclerosis       Date:  1978-08       Impact factor: 5.162

2.  Properties of the plasma very low and low density lipoproteins in Tangier disease.

Authors:  R J Heinen; P N Herbert; D S Fredrickson
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

3.  Dynamic properties of human high density lipoprotein apoproteins.

Authors:  J Shepherd; J R Patsch; C J Packard; A M Gotto; O D Taunton
Journal:  J Lipid Res       Date:  1978-03       Impact factor: 5.922

4.  The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins.

Authors:  H B Brewer; T Fairwell; A LaRue; R Ronan; A Houser; T J Bronzert
Journal:  Biochem Biophys Res Commun       Date:  1978-02-14       Impact factor: 3.575

5.  Metabolism of high-density lipoprotein apolipoproteins in Tangier disease.

Authors:  E J Schaefer; C B Blum; R I Levy; L L Jenkins; P Alaupovic; D M Foster; H B Brewer
Journal:  N Engl J Med       Date:  1978-10-26       Impact factor: 91.245

6.  Tangier disease: one explanation of lipid storage.

Authors:  P N Herbert; T Forte; R J Heinen; D S Fredrickson
Journal:  N Engl J Med       Date:  1978-09-07       Impact factor: 91.245

7.  Apoprotein A-I synthesis in normal intestinal mucosa and in Tangier disease.

Authors:  R M Glickman; P H Green; R S Lees; A Tall
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

8.  Human chylomicron apolipoprotein metabolism.

Authors:  E J Schaefer; L L Jenkins; H B Brewer
Journal:  Biochem Biophys Res Commun       Date:  1978-01-30       Impact factor: 3.575

9.  Abnormal concentration and anomalous distribution of apolipoprotein A-I in Tangier disease.

Authors:  L O Henderson; P N Herbert; D S Fredrickson; R J Heinen; J C Easterling
Journal:  Metabolism       Date:  1978-02       Impact factor: 8.694

10.  Plasma-triglycerides in regulation of H.D.L.-cholesterol levels.

Authors:  E J Schaefer; R I Levy; D W Anderson; R N Danner; H B Brewer; W C Blackwelder
Journal:  Lancet       Date:  1978-08-19       Impact factor: 79.321

View more
  11 in total

Review 1.  Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity.

Authors:  Eric Champagne; Laurent O Martinez; Pierre Vantourout; Xavier Collet; Ronald Barbaras
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  In vivo metabolism of proapolipoprotein A-I in Tangier disease.

Authors:  D Bojanovski; R E Gregg; L A Zech; M S Meng; C Bishop; R Ronan; H B Brewer
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

3.  Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter.

Authors:  S Santamarina-Fojo; K Peterson; C Knapper; Y Qiu; L Freeman; J F Cheng; J Osorio; A Remaley; X P Yang; C Haudenschild; C Prades; G Chimini; E Blackmon; T Francois; N Duverger; E M Rubin; M Rosier; P Denèfle; D S Fredrickson; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma.

Authors:  C Edelstein; J I Gordon; C A Vergani; A L Catapano; V Pietrini; A M Scanu
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

5.  Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis.

Authors:  N H Choi-Miura; T Sakamoto; S Ohtaki; H Nakamura; S Ishizawa; Y Takagi; K Gomi; M Tomita
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Nucleotide sequence and the encoded amino acids of human apolipoprotein A-I mRNA.

Authors:  S W Law; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

7.  Familial disorders of plasma apolipoproteins.

Authors:  C R Sirtori; G Franceschini
Journal:  Klin Wochenschr       Date:  1985-06-03

8.  Tangier disease. A case with sensorimotor distal polyneuropathy and lipid accumulation in striated muscle and vasa nervorum.

Authors:  A Marbini; F Gemignani; G Ferrarini; S Maccari; B Lucci; M M Bragaglia; C Plancher; C Vergani
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

9.  Tangier disease: a disorder of intracellular membrane traffic.

Authors:  G Schmitz; G Assmann; H Robenek; B Brennhausen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Eleni A Karavia; Dionysios J Papachristou; Kassiani Liopeta; Irene-Eva Triantaphyllidou; Odyssefs Dimitrakopoulos; Kyriakos E Kypreos
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.